$61.26
2.70% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Incyte Stock price

$61.26
-0.01 0.02% 1M
+2.00 3.38% 6M
-1.53 2.44% YTD
-1.93 3.05% 1Y
-14.83 19.49% 3Y
-17.98 22.69% 5Y
+8.67 16.49% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-1.70 2.70%
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Key metrics

Market capitalization $11.80b
Enterprise Value $10.32b
P/E (TTM) P/E ratio 172.61
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.67
P/S ratio (TTM) P/S ratio 3.06
P/B ratio (TTM) P/B ratio 3.92
Revenue growth (TTM) Revenue growth 9.78%
Revenue (TTM) Revenue $3.86b
EBIT (operating result TTM) EBIT $33.74m
Free Cash Flow (TTM) Free Cash Flow $-138.12m
Cash position $1.52b
EPS (TTM) EPS $0.35
P/E forward 69.16
P/S forward 2.85
EV/Sales forward 2.49
Short interest 10.86%
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Incyte forecast:

13x Buy
52%
11x Hold
44%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a Incyte forecast:

Buy
52%
Hold
44%
Sell
4%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
3,857 3,857
10% 10%
100%
- Direct Costs 332 332
14% 14%
9%
3,525 3,525
9% 9%
91%
- Selling and Administrative Expenses 1,017 1,017
0% 0%
26%
- Research and Development Expense 2,388 2,388
41% 41%
62%
121 121
77% 77%
3%
- Depreciation and Amortization 87 87
17% 17%
2%
EBIT (Operating Income) EBIT 34 34
92% 92%
1%
Net Profit 97 97
73% 73%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
Business Wire
17 days ago
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at ESMO Congress 2024.
Positive
Seeking Alpha
19 days ago
Incyte Corporation reported positive results achieved from Phase 3 study using Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma. Supplemental Biologics License Application filing for label expansion of Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma, expected by end of 2024. It is expected that the 7 major follicular lymphoma ...
Positive
Reuters
23 days ago
Incyte said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer.
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,524
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today